These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12942041)

  • 21. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
    Kohn EC; Reed E; Sarosy GA; Minasian L; Bauer KS; Bostick-Bruton F; Kulpa V; Fuse E; Tompkins A; Noone M; Goldspiel B; Pluda J; Figg WD; Liotta LA
    Clin Cancer Res; 2001 Jun; 7(6):1600-9. PubMed ID: 11410496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
    Kim TY; Kim DW; Chung JY; Shin SG; Kim SC; Heo DS; Kim NK; Bang YJ
    Clin Cancer Res; 2004 Jun; 10(11):3708-16. PubMed ID: 15173077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.
    Jones SF; Infante JR; Thompson DS; Mohyuddin A; Bendell JC; Yardley DA; Burris HA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):471-5. PubMed ID: 22851205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
    van Zuylen L; Sparreboom A; van der Gaast A; van der Burg ME; van Beurden V; Bol CJ; Woestenborghs R; Palmer PA; Verweij J
    Clin Cancer Res; 2000 Apr; 6(4):1365-71. PubMed ID: 10778964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
    Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
    Amato RJ; Sarao H
    Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
    Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
    Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
    Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
    Vogt HG; Martin T; Kolotas C; Schneider L; Strassmann G; Zamboglou N
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-101-S12-105. PubMed ID: 9331131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study.
    Rosenthal DI; Okani O; Corak J; Kavanaugh D; Kamen B; Vuitch FM; Gazdar AF; Greiner J; Frenkel EF; Carbone DP
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-96-S12-100. PubMed ID: 9331130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
    Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK
    Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
    Kobayashi H; Eckhardt SG; Lockridge JA; Rothenberg ML; Sandler AB; O'Bryant CL; Cooper W; Holden SN; Aitchison RD; Usman N; Wolin M; Basche ML
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):329-36. PubMed ID: 15906031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.
    Chang AY; Boros L; Asbury R; Hui L; Rubins J
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-69-S17-71. PubMed ID: 9374098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
    Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of paclitaxel with oral etoposide in advanced solid tumors.
    Perez EA; Coe T; Turrell C; Lau D; Campbell D; Gandara D
    Cancer J Sci Am; 1996; 2(5):286-90. PubMed ID: 9166546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
    Kelly WK; Zhu AX; Scher H; Curley T; Fallon M; Slovin S; Schwartz L; Larson S; Tong W; Hartley-Asp B; Pellizzoni C; Rocchetti M
    Clin Cancer Res; 2003 Jun; 9(6):2098-107. PubMed ID: 12796374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.